Pietro's Fight

Pietro's Fight is a disease-specific charitable foundation, not an investment entity. It raises and deploys philanthropic dollars for Duchenne Muscular Dystrophy research and awareness, without seeking financial returns. The firm's own website presents it purely as a donor-funded nonprofit with no investment-committee or portfolio-company disclosures.

No. The foundation does not make venture-capital or private-equity investments. Its capital deployment model is grantmaking to academic researchers, clinical programs, and awareness campaigns. There is no evidence of a for-profit investment vehicle or direct equity participation in any company pursuing DMD therapies.

The foundation publicly celebrated the FDA's approval of Exondys 51 (eteplirsen), the first disease-modifying drug approved for DMD. While a direct causal link between its grants and the approval cannot be established from public filings, the organization positions itself as a consistent funder of the DMD research ecosystem that helped advance the therapy.

Pietro's Fight raises money through community events — including an annual 5K run in Brooklyn and charity raffles — plus individual donations channeled through its website. It does not report an endowment, a corporate sponsor roster, or institutional grants, and it does not operate a revenue-generating investment portfolio.

Dayna and Manni Scarso, Pietro's parents, co-founded and operate the foundation. They serve as the public faces of the organization, featured on the website as the narrators of its mission. No separate board, investment committee, or professional staff beyond the founders has been publicly disclosed.